OKT3 does not affect leukemic initiating cell/SRC engraftment
| 1° Patient sample . | Type . | Leukemia engraftment . | |
|---|---|---|---|
| Mock treated . | OKT3 treated . | ||
| CCHMC2013-10 (PB) | B-ALL | 94 | 92 |
| CCHMC2013-11 (BM) | AML | 20 | 56 |
| CCHMC2013-11 (PB) | AML | 84 | 87 |
| CCHMC2013-15 (BM) | AML | 81, 87 | 70, 65, 80 |
| CCHMC2013-17 (BM) | AML | 10, 1 | 15, 1 |
| CCHMC2013-18 (PB) | B-ALL | 94, 95 | 91, 93 |
| CCHMC2013-19 (BM) | AML | 70, 71 | 78, 82 |
| CCHMC2013-22 (BM) | B-ALL | 12, 10, 30 | 7, 19, 23 |
| CCHMC2013-24 (PB) | B-ALL | 48, 34 | 34, 25 |
| 1° Patient sample . | Type . | Leukemia engraftment . | |
|---|---|---|---|
| Mock treated . | OKT3 treated . | ||
| CCHMC2013-10 (PB) | B-ALL | 94 | 92 |
| CCHMC2013-11 (BM) | AML | 20 | 56 |
| CCHMC2013-11 (PB) | AML | 84 | 87 |
| CCHMC2013-15 (BM) | AML | 81, 87 | 70, 65, 80 |
| CCHMC2013-17 (BM) | AML | 10, 1 | 15, 1 |
| CCHMC2013-18 (PB) | B-ALL | 94, 95 | 91, 93 |
| CCHMC2013-19 (BM) | AML | 70, 71 | 78, 82 |
| CCHMC2013-22 (BM) | B-ALL | 12, 10, 30 | 7, 19, 23 |
| CCHMC2013-24 (PB) | B-ALL | 48, 34 | 34, 25 |
Leukemic engraftment from non-GVHD–inducing primary patient specimens pretreated with or without OKT3 is shown. Engraftment is shown as the percentage of BM double positive for CD45 and either CD33 (acute myeloid leukemia [AML]) or CD19 (B cell acute lymphoblastic leukemia [B-ALL]) by flow cytometry. NRG or NSG mice were used for B-ALL samples, and NSGS or NRGS mice were used for AML samples.